We have a robust pipeline of wholly owned and partnered programmes to address a broad spectrum of disease indications.
Our foundation is built on our proprietary soluble TCR bi-specific ImmTAC® platform.
12 April 2021Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting
25 March 2021Immunocore Provides Business Update and Reports Full Year 2020 Financial Results
11 March 2021Immunocore Announces Upcoming Presentations at the American Association for Cancer Research 2021 Annual Meeting